17.37
-0.49
(-2.74%)
At close: 3:30:02 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,261,267
1,043,350
1,295,678
1,371,267
2,023,795
Cost of Revenue
967,601
756,397
1,064,724
943,429
1,136,935
Gross Profit
293,666
286,953
230,954
427,838
886,860
Operating Expense
409,539
371,267
411,940
404,588
572,448
Operating Income
-115,873
-84,314
-180,986
23,250
314,412
Net Non Operating Interest Income Expense
-31,799
-19,668
-41,625
190
-20,156
Pretax Income
-132,340
-191,125
-422,651
-61,391
294,914
Tax Provision
25,323
26,181
-36,444
-8,078
67,137
Net Income Common Stockholders
-157,664
-217,306
-386,207
-53,313
227,777
Diluted NI Available to Com Stockholders
-157,664
-217,306
-386,207
-53,313
227,777
Basic EPS
-3.15
-4.34
-7.71
-1.06
5.60
Diluted EPS
-3.15
-4.34
-7.71
-1.06
5.60
Basic Average Shares
51,273.11
50,101.24
50,101.24
50,295.28
40,672.67
Diluted Average Shares
51,273.11
50,101.24
50,101.24
50,295.28
40,672.67
Rent Expense Supplemental
--
2,355
2,722
1,976
4,201
Total Expenses
1,377,140
1,127,664
1,476,664
1,348,017
1,709,383
Net Income from Continuing & Discontinued Operation
-157,664
-217,306
-386,207
-53,313
227,777
Normalized Income
-153,969.40
-155,894.30
-210,538.74
14,130.88
228,241.18
Interest Income
--
247
274
838
490
Interest Expense
--
19,738
41,538
245
16,760
Net Interest Income
-31,799
-19,668
-41,625
190
-20,156
EBIT
-202,946
-171,387
-381,113
-61,146
311,674
EBITDA
-92,330
-64,661
-246,923
83,963
469,915
Reconciled Cost of Revenue
967,601
756,397
1,064,724
943,429
1,136,935
Reconciled Depreciation
110,616
106,726
134,190
145,109
158,241
Net Income from Continuing Operation Net Minority Interest
-157,664
-217,306
-386,207
-53,313
227,777
Total Unusual Items Excluding Goodwill
-5,278
-87,731
-192,245
-77,663
-601
Total Unusual Items
-5,278
-87,731
-192,245
-77,663
-601
Normalized EBITDA
-87,052
23,070
-54,678
161,626
470,516
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-1,583.40
-26,319.30
-16,576.74
-10,219.12
-136.82
3/31/2021 - 9/21/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NECLIFE.BO Nectar Lifesciences Limited
21.90
-3.27%
SYNCOMF.NS Syncom Formulations (India) Limited
16.76
+2.63%
SUVEN.NS Suven Life Sciences Limited
122.30
+2.49%
SIGACHI.NS Sigachi Industries Limited
38.00
+2.43%
AARTIPHARM.NS Aarti Pharmalabs Limited
679.40
+8.81%
MOREPENLAB.NS Morepen Laboratories Limited
50.20
+3.91%
PPLPHARMA.NS Piramal Pharma Limited
219.83
+5.50%
ZYDUSLIFE.NS Zydus Lifesciences Limited
868.85
+2.90%
AUROPHARMA.NS Aurobindo Pharma Limited
1,082.45
+2.31%
NATCOPHARM.NS NATCO Pharma Limited
775.50
+3.88%